Compounded semaglutide: is it safe and legal to keep using in 2026? If you are asking, you are probably on it, or close to someone who is, and the answers you have found are either alarming or reassuring, rarely both, and almost never dated. You want the facts in order, what they mean for the vial in your refrigerator, and what to do next.
This piece gives you the record as it stands in October 2026, with each fact sourced. GoodLife Health is a clinician-led membership that prescribes branded, FDA-approved medication only and never compounded GLP-1, so we are not neutral, and we will say plainly where our view begins. The facts come first.
- Legal: the broad basis for mass-producing compounded semaglutide ended in 2025, when the FDA declared the shortage resolved on February 21 and the grace periods closed on April 22 for 503A pharmacies and May 22 for 503B facilities.
- What remains legal is narrow: compounding for an individual patient with a documented clinical reason the approved product cannot meet.
- Safe: compounded semaglutide is not FDA-approved, and the FDA does not review it for safety, effectiveness or quality; the agency has recorded dosing errors and warned about salt forms.
- We do not say compounded semaglutide is dangerous in itself. We say its safety is not established the way an approved medicine's is, and that the responsibility sits with the prescriber.
- If you are on it now, do not stop or change your dose alone; a clinician can review your history and labs and decide a branded path with you.
Why the answers you have read disagree
Most of what you will find about compounded semaglutide was written at one of three moments: during the shortage, when compounding was a legal response to scarcity; during the months after the shortage ended, when the rules were being wound down; or by a seller with something to sell. Each is accurate about its own moment and misleading about yours. That is why one source tells you it is legal and fine, and another tells you it is illegal and risky, and neither gives a date.
The useful question is narrower than "is it safe and legal". It is: what does the law allow now, who does it apply to, and what is actually known about the product you have?
The legal record, in order
The shortage. For several years semaglutide, the active ingredient in Wegovy and Ozempic, was on the FDA's drug shortage list. Federal law lets pharmacies compound copies of a drug while it is in shortage, so two kinds of pharmacy could make semaglutide products: 503A pharmacies, which are state-licensed and compound for individual patients, and 503B outsourcing facilities, which register with the FDA and can produce in larger volume.
The resolution. The FDA declared the semaglutide shortage resolved on February 21, 2025. Its page on medications containing semaglutide and tirzepatide sets out what followed.
The wind-down. Compounders were given a grace period to stop making shortage-era copies. It ended on April 22, 2025 for 503A pharmacies and on May 22, 2025 for 503B outsourcing facilities.
What is left. A 503A pharmacy may still compound for an individual patient when a prescriber documents a clinical reason the approved product cannot meet, an allergy to an ingredient in the branded product, for example. That is a real pathway, and a much smaller one than the market of online clinics that grew during the shortage.
What this means for you as a patient is simpler than it sounds. The legal obligations fall on the pharmacy and the prescriber, not on you. The practical consequence for you is that a product sold to many patients as a routine substitute for Wegovy, after May 2025, sits outside the pathway the law still allows, and the clinic and pharmacy behind it have taken that position on your behalf.
What is known about safety, and what is not
The FDA's position is stated plainly on its page on unapproved GLP-1 drugs used for weight loss: compounded drugs are not FDA-approved, and the agency does not review them for safety, effectiveness or quality before they are marketed. Three specific concerns appear in its record.
Dosing errors. The FDA has received adverse event reports involving compounded semaglutide, including dosing errors, some from patients measuring their own doses from multi-dose vials in units rather than receiving a fixed dose from a pen.
Salt forms. The FDA has warned that some products sold as semaglutide were made from semaglutide sodium or semaglutide acetate. These salt forms are not the active ingredient in the approved medicines.
Added ingredients. Some compounded versions have been made with additional ingredients that are not in the approved product.
What is not known is just as important. The large published trials of semaglutide were run on the approved medicine. No trial tells you how a particular compounded product performs, because none has been run on it. That is the honest meaning of "not established": we do not know it is unsafe, and we do not know it is equivalent.
We do not say compounded semaglutide is dangerous in itself, and we would be wary of anyone who says so without a source. We say that its safety rests on the practices of one pharmacy rather than on a reviewed and labeled manufacturing process, and that when a clinician prescribes it, that clinician's licence carries the responsibility for what is in the vial.
If you are on compounded semaglutide, do not stop it suddenly or change the dose on your own. Keep the label, note the concentration and the dose you inject in units, and bring both to a clinician, who decides whether and how to move you to an approved medicine.


What to check about the product you have now
You can learn a good deal from what is already in your hands.
The label. Does it name semaglutide, or semaglutide sodium or semaglutide acetate? Does it list other ingredients? What concentration is it, in milligrams per milliliter?
The pharmacy. Is it a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility? A registration tells you the facility operates under a recognized framework. It does not tell you that a particular vial matches its label.
The prescriber. Did anyone document a clinical reason you need a compounded product instead of the approved one? Has anyone drawn labs since you started? When your progress slowed, did anyone look for a reason before raising the dose?
The price trend. Has your monthly cost risen each time the dose went up? That tells you how the clinic earns its money, which is worth knowing before you agree to the next step.
If you decide to stay on it for now
Some readers will finish this piece and keep their current product for a while, because changing anything mid-treatment is a decision that deserves time. If that is you, a few habits make the period safer and the eventual decision easier.
Keep every label, and do not mix products or pharmacies; a new vial from a different source can have a different concentration even when the name is the same. Write down the dose you inject in units and the date each time it changes. Report side effects to your prescriber as they happen, and ask what they would do about them. Ask for labs: fasting insulin, A1C, a lipid panel and thyroid function tell you whether the medicine is changing what it is meant to change. And if the next step offered is a higher dose, ask what was checked first.
None of this is a substitute for a clinician who knows your history. It is a way of keeping the record you will want when you sit down with one.
Where we stand, and why
GoodLife Health's clinicians prescribe branded, FDA-approved GLP-1 medication when it is clinically indicated, Wegovy, Ozempic, Zepbound or Mounjaro, and never compounded GLP-1. We prescribe to the pharmacy you choose, and you pay that pharmacy its own price. We set nothing on the medication, see nothing on it and take nothing from it.
The reason is responsibility. A prescription is a clinician's judgment backed by a licence, and we want that judgment applied to a medicine whose contents and dose are on the label and whose evidence comes from trials of that medicine. The reason is also how the care works. Our clinicians work to a rule our clinical lead puts in one sentence: "I don't automatically increase a GLP-1 every month because the dosing schedule says that another dose exists." When progress stalls, the first step is the labs.
Where this is going
The compounding wave was a response to scarcity, and the record since 2025 shows the scarcity ending. Both GLP-1 shortages have been declared resolved. The manufacturers now sell branded medicine to self-pay patients at published prices: through NovoCare, Wegovy pens were listed in September 2026 at $199 a month for the first two fills, an introductory offer for new patients through December 2026, and $349 a month after, with the Wegovy pill from $149 a month at lower doses, according to NovoCare's Wegovy page.
We think the next phase is diagnosis-led: the branded medicine bought honestly at the pharmacy's price, and the care around it, the testing, the trend and the clinician, paid for as care. That is a better answer to "is it safe" than any vial could give, because it asks why you need the medicine before it asks how much.
What it costs, what it buys, and what it does not
The GoodLife Health membership is $299 a month, month to month. $598 is held on your card at sign-up, charged only once you are accepted, and covers the first two months. If a clinician cannot accept you into care, the $598 hold is released and you are never charged; once you are accepted, the first two months are non-refundable. Medication billed by a pharmacy follows that pharmacy's own return and refund policy. The fee is the same whatever the medication and whatever the dose.
It buys four cardiometabolic lab panels a year, including fasting insulin, A1C, ApoB and thyroid function, with every result in your hands; a clinician licensed in your state who stays; messaging and video visits; and branded medication prescribed when indicated to your pharmacy at its price. It returns a diagnosis and a trend. It does not replace your health insurance, and it does not guarantee weight loss, coverage of a medication or acceptance into care.
Who this is not for
If you want to keep a compounded product at the lowest possible price, GoodLife Health is not for you; we do not compete with the $99-a-month compounded app and will not prescribe compounded GLP-1. The membership is also wrong for someone who wants a prescription without labs, for anyone under 18, pregnant or planning a pregnancy on a GLP-1, for someone who needs urgent or full-scope primary care, and for anyone outside the United States. If $299 a month would be a strain, choose care you can sustain.
We do not know it is unsafe, and we do not know it is equivalent; that is what "not established" means.
Frequently Asked Questions
Is compounded semaglutide legal in 2026?
Mass production as a substitute for Wegovy is no longer allowed: the FDA declared the shortage resolved on February 21, 2025, and the grace periods ended on April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B facilities. Compounding for an individual patient with a documented clinical reason remains legal.
Is compounded semaglutide safe?
Its safety is not established the way an approved medicine's is. It is not FDA-approved, the FDA does not review it before sale, and the agency has recorded dosing errors and warned about salt forms. We do not say it is dangerous in itself.
Am I breaking the law by using compounded semaglutide?
The legal obligations fall on the pharmacy and the prescriber, not the patient. The practical question for you is what is in your vial and whether anyone is following your labs.
What should I do if I want to stop compounded semaglutide?
Do not stop suddenly or change your dose alone. Bring the label and your dose history to a clinician, who can review your labs and decide with you whether to move to a branded medicine and at what dose.
Related Reading
- Compounded GLP-1 vs Brand Name: What Patients Need to Know
- How GLP-1 Telehealth Companies Make Money: A Plain-Language Whitepaper
- Aligned Medicine: How Zero-Markup Healthcare Actually Works
- What Is GoodLife Health?
References
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- FDA: Medications Containing Semaglutide and Tirzepatide, Safety Information and Compounding. 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
- NovoCare Pharmacy: Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html